welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Cl...IMPORTANCE: Patients with familial aden...
-
A Randomized Controlled Trial of Eicosapentaenoic acid and/or Aspirin For Colorectal Adenoma Prevention During Colon...BACKGROUND: The naturally-occurring ome...
-
Nutritional Agents With Anti-inflammatory Properties in Chemoprevention of Colorectal NeoplasiaThe strong link between inflammation and...
-
Eviendep Reduces Number and Size of Duodenal Polyps in Familial Adenomatous Polyposis Patients With Ileal Pouch-Anal...AIM: To evaluate if 3 mo oral supplemen...
-
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive FibromatosisBackground: Desmoid tumors (also known a...
-
Familial Adenomatous Polyposis (FAP) – Inheritedhttps://my.clevelandclinic.org/ccf/media...
-
Laparoscopic-Assisted Ileal Pouch-Rectal Muscle Sheath Anastomosis for the Treatment of Familial Adenomatous Polypos...PURPOSE: Familial adenomatous polyposis...